MX2021011008A - Compuestos piperidinil biciclicos fusionados y relacionados como modulares del receptor c5a. - Google Patents

Compuestos piperidinil biciclicos fusionados y relacionados como modulares del receptor c5a.

Info

Publication number
MX2021011008A
MX2021011008A MX2021011008A MX2021011008A MX2021011008A MX 2021011008 A MX2021011008 A MX 2021011008A MX 2021011008 A MX2021011008 A MX 2021011008A MX 2021011008 A MX2021011008 A MX 2021011008A MX 2021011008 A MX2021011008 A MX 2021011008A
Authority
MX
Mexico
Prior art keywords
receptor
related compounds
modulators
bicyclic
fused
Prior art date
Application number
MX2021011008A
Other languages
English (en)
Inventor
Yong Li
Niels Christoph Riedemann
Renfeng Guo
Original Assignee
Inflarx Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inflarx Gmbh filed Critical Inflarx Gmbh
Publication of MX2021011008A publication Critical patent/MX2021011008A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención actual se refiere a piperidinilo bicíclico de piperidinilo fusionado, piperidinilo sustituido en meta y sus compuestos relacionados que modulan las actividades del receptor C5a de mamífero que se unen directamente al receptor C5a. La invención también se refiere a composiciones farmacéuticas que contienen tales compuestos y su uso en el tratamiento de una enfermedad o trastorno que implica la activación patógena de los receptores C5a.
MX2021011008A 2019-03-11 2020-02-07 Compuestos piperidinil biciclicos fusionados y relacionados como modulares del receptor c5a. MX2021011008A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962816726P 2019-03-11 2019-03-11
EP19177349 2019-05-29
US201962873612P 2019-07-12 2019-07-12
PCT/EP2020/053171 WO2020182384A1 (en) 2019-03-11 2020-02-07 Fused piperidinyl bicyclic and related compounds as modulators of c5a receptor

Publications (1)

Publication Number Publication Date
MX2021011008A true MX2021011008A (es) 2021-10-13

Family

ID=69526272

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011008A MX2021011008A (es) 2019-03-11 2020-02-07 Compuestos piperidinil biciclicos fusionados y relacionados como modulares del receptor c5a.

Country Status (14)

Country Link
US (2) US11149009B2 (es)
EP (1) EP3938351A1 (es)
JP (1) JP7360745B2 (es)
KR (1) KR20210137157A (es)
CN (1) CN113784955A (es)
AU (1) AU2020234859A1 (es)
BR (1) BR112021017756A2 (es)
CA (1) CA3129019A1 (es)
CL (1) CL2021002357A1 (es)
IL (1) IL285630A (es)
MX (1) MX2021011008A (es)
PE (1) PE20220167A1 (es)
SG (1) SG11202108957RA (es)
WO (1) WO2020182384A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
WO2018184739A1 (en) 2017-04-03 2018-10-11 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of c5a activity
MX2022005522A (es) * 2019-11-08 2022-06-08 Chemocentryx Inc Formas de sal de un receptor de componente c5a de complemento.
CA3155542A1 (en) 2019-11-08 2021-05-14 Kwok YAU Amorphous form of a complement component c5a receptor
MX2023001504A (es) * 2020-08-07 2023-04-27 Kira Pharmaceuticals Suzhou Ltd Compuestos como inhibidores del receptor del componente complemento 5a (c5ar).

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704355A (en) 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
AU6501390A (en) 1989-09-21 1991-04-18 Synergen, Inc. Method for transporting compositions across the blood brain barrier
US20070112015A1 (en) * 2005-10-28 2007-05-17 Chemocentryx, Inc. Substituted dihydropyridines and methods of use
WO2010075257A1 (en) 2008-12-22 2010-07-01 Chemocentryx, Inc. C5ar antagonists
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
WO2018184739A1 (en) 2017-04-03 2018-10-11 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of c5a activity
CN108440514A (zh) * 2018-05-16 2018-08-24 张玉叶 一种甲酰胺类衍生物、制备方法及其在抗肿瘤药物中的应用
CN108727355A (zh) * 2018-05-16 2018-11-02 张玉叶 一种甲酰胺类衍生物、制备方法及其在抗肿瘤药物中的应用
CN108558844A (zh) * 2018-05-16 2018-09-21 张玉叶 一种甲酰胺类衍生物及其在抗肿瘤药物中的应用
CN108727354A (zh) * 2018-05-16 2018-11-02 张玉叶 一种甲酰胺类衍生物及其在抗肿瘤药物中的应用
CN108440513A (zh) 2018-05-16 2018-08-24 张玉叶 一种甲酰胺类衍生物及其在抗肿瘤药物中的应用

Also Published As

Publication number Publication date
AU2020234859A1 (en) 2021-09-16
WO2020182384A1 (en) 2020-09-17
US11149009B2 (en) 2021-10-19
US20200290969A1 (en) 2020-09-17
PE20220167A1 (es) 2022-01-28
CN113784955A (zh) 2021-12-10
KR20210137157A (ko) 2021-11-17
SG11202108957RA (en) 2021-09-29
US20210403433A1 (en) 2021-12-30
JP7360745B2 (ja) 2023-10-13
CL2021002357A1 (es) 2022-04-22
CA3129019A1 (en) 2020-09-17
BR112021017756A2 (pt) 2021-11-16
EP3938351A1 (en) 2022-01-19
JP2022524544A (ja) 2022-05-06
IL285630A (en) 2021-09-30

Similar Documents

Publication Publication Date Title
MX2021011008A (es) Compuestos piperidinil biciclicos fusionados y relacionados como modulares del receptor c5a.
MX2021007320A (es) Moleculas agonistas de union al antigeno cd28 que actuan sobre el tumor.
MD20170081A2 (ro) Compuşi 4,6-diamino-pirido[3,2-D]pirimidină modulatori ai receptorilor de tip Toll
PH12019550155A1 (en) ARYL HYDROCARBON RECEPTOR (AhR) MODULATOR COMPOUNDS
NZ737399A (en) Ccr2 modulators
MX2016012830A (es) Anticuerpos contra el receptor 2 del factor de crecimiento epidermico humano (her2) biespecificos.
MX2021015508A (es) Carbamatos de piridina y su uso como moduladores del receptor glun2b.
PH12019550135A1 (en) Aryl hydrocarbon receptor (ahr) modulator compounds
CL2015002123A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
PH12019550136A1 (en) ARYL HYDROCARBON RECEPTOR (AhR)MODULATOR COMPOUNDS
MX2021015511A (es) Carbamatos de pirazina y sus usos como moduladores del receptor glun2b.
TW201613902A (en) Difluoropyrrolidines as orexin receptor modulators
ZA201907746B (en) 6-5 fused rings as c5a inhibitors
EA201691853A1 (ru) Агонисты мускариновых рецепторов
IN2014CN03903A (es)
MX2019014292A (es) Anillos 5-5 fusionados como inhibidores c5a.
JOP20210328A1 (ar) مركبات أميدات بيريدين-بيرازولو المستبدلة واستخدامها باعتبارها معدِّلات لمستقبل الغلوتومات "glun2b"
MX2021015500A (es) Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b.
MX2023000677A (es) Compuestos moduladores de receptor de estrogeno.
EP4219507A3 (en) Thienopyrimidinone nmda receptor modulators and uses thereof
MX2022011310A (es) Azabiciclo y derivados de diazepina para tratar trastornos oculares.
EA202192472A1 (ru) КОНДЕНСИРОВАННЫЕ ПИПЕРИДИНИЛЬНЫЕ БИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ И РОДСТВЕННЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРА C5a
JOP20210331A1 (ar) مُعَدِّلات مُستقبِل نمدا (nmda)
JOP20210332A1 (ar) عقاقير أولية لمعدلات المستقبل nmda
MX2020003185A (es) Nuevos compuestos heterociclicos.